Lunit Inc. (KOSDAQ:328130)

South Korea · Delayed Price · Currency is KRW

14,980

+590 (4.10%)

Oct 29, 2026, 3:30 PM KST

Market Cap	1.12T -4.4%
Revenue (ttm)	91.82B +24.3%
Net Income	-55.69B
EPS	-1,434.27
Shares Out	74.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,337,396
Open	15,450
Previous Close	14,390
Day's Range	14,040 - 16,290
52-Week Range	8,180 - 24,900
Beta	1.20
Analysts	n/a
Price Target	10,150.00 (-32.24%)
Est. Earnings	Nov 11, 2026

About Lunit

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such a... [Read more]

Industry Medical - Healthcare Information Services

Sector Healthcare

Founded 2013

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 328130

Full Company Profile

Financial Performance

In 2025, Lunit's revenue was 83.13 billion, an increase of 53.43% compared to the previous year's 54.18 billion. Losses were -47.39 billion, -42.69% less than in 2024.

Financial Statements

Analyst Summary

The average 12-month stock price target for 328130 is ₩10,150, which is a decrease of -32.24% from the latest price.

Price Target

₩10,150

(-32.24% downside)

Stock Forecasts